Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 1.00 |
| ▸ | KCNN3 | Q9UGI6 | 14/20 | 0.51 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.51 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29344715 | 0.80 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL30974 | 0.80 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2CHEK1 | |
| SCHEMBL659433 | 0.80 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL1018372 | 0.80 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2CHEK1 | |
| SCHEMBL13022182 | 0.80 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2DPP4 | |
| SCHEMBL1290450 | 0.80 | PDE10A (0.67) | PDE10AKCNN3KCNN1KCNN2DPP4 | |
| SCHEMBL312516 | 0.78 | PDE10A (0.64) | PDE10ACDK2 | |
| SCHEMBL12363999 | 0.76 | PDE10A (0.61) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL1695626 | 0.76 | PDE10A (0.61) | PDE10AKCNN3KCNN1KCNN2 | |
| SCHEMBL14242902 | 0.76 | PDE10A (0.61) | PDE10AKCNN3KCNN1KCNN2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 456 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110016036-B | Pyrazolo [1,5-a ] pyrimidine compound and preparation method and application thereof | 辽宁大学 | 2022-06-03 | — | — | CN | claimed |
| CN-122094954-A | Tricyclic quinolones and 1, 8-naphthyridin-2-one BCL6 difunctional degrading agents | — | 2026-05-26 | — | — | CN | disclosed |
| CN-115943145-B | Pyrazolopyrimidine compounds as ATR kinase inhibitors | BEIJING TIDE PHARMACEUTICAL CO.,LTD. (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-12595263-B2 | Pyrazolopyrimidine compound used as ATR kinase inhibitor | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-4717312-A1 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES USEFUL AS A MEDICAMENT | Perha Pharmaceuticals (FR) | 2026-04-01 | — | — | EP | disclosed |
| EP-3778604-B1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA FARBER CANCER INST INC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2025-10-16 | — | — | US | disclosed |
| US-20250270174-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| EP-1671962-A1 | NOVEL FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-21 | — | — | EP | disclosed |
| EP-1666468-A1 | CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-0628559-B1 | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF LILLY GMBH (DE) | 2002-04-03 | — | — | EP | disclosed |
| US-5602137-A | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5602136-A | Pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1997-02-11 | — | — | US | disclosed |
| US-5571813-A | Fused pyrimidine compounds and their use as pharmaceuticals | BEIERSDORF-LILLY GMBH (DE) | 1996-11-05 | — | — | US | disclosed |
| EP-0628559-A1 | Pyrimidine compounds and their use as pharmaceuticals | Beiersdorf-Lilly GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| US-4908056-A | Herbicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-13 | — | — | US | disclosed |
| US-4838925-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-06-13 | — | — | US | disclosed |
| EP-0244166-A2 | Heterocyclic acetyl sulfonamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | PIKFYVE, TARDBP, TDP1 | PDE10A 2113/4885KCNN3 2131/4885KCNN1 2468/4885 |
| US-20250320219-A1 | SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF | ATR, CHEK1, CHEK2 | PDE10A 3802/4885KCNN3 4247/4885KCNN1 4054/4885 |
| US-20250270174-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | PDE10A 330/4885KCNN3 1294/4885KCNN1 1024/4885 |
| US-12479848-B2 | Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof | ATR, CHEK1, CHEK2 | PDE10A 3837/4885KCNN3 4251/4885KCNN1 4041/4885 |
| US-12595263-B2 | Pyrazolopyrimidine compound used as ATR kinase inhibitor | ATR, CHEK1, ATRIP | PDE10A 3700/4885KCNN3 2925/4885KCNN1 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.